One-day treatment of small molecule 8-bromo-cyclic AMP analogue induces cell-based VEGF production for in vitro angiogenesis and osteoblastic differentiation

Journal of Tissue Engineering and Regenerative Medicine

Volumn 10, Issue 10, 2016, Pages 867-875

  Lo, Kevin W H ^a,b   Kan, Ho Man ^a   Gagnon, Keith A ^a   Laurencin, Cato T ^a,b  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

angiogenesis; bone regeneration; cAMP; morphogenesis; osteoblastic differentiation; regenerative engineering; small molecules

Indexed keywords

BONE; CELL ENGINEERING; CELL PROLIFERATION; COPYRIGHTS; ENDOTHELIAL CELLS; MOLECULES;

8-BR-CAMP; ANGIOGENESIS; BONE REGENERATION; CAMP; IN-VITRO; MC3T3-E1 CELL; MORPHOGENESIS; OSTEOBLASTIC DIFFERENTIATION; REGENERATIVE ENGINEERING; SMALL MOLECULES;

TISSUE REGENERATION;

8 BROMO CYCLIC AMP; ALKALINE PHOSPHATASE; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; BONE MATRIX; BONE MINERALIZATION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN SYNTHESIS; UMBILICAL VEIN ENDOTHELIAL CELL;

EID: 85027952550     PISSN: 19326254     EISSN: 19327005     Source Type: Journal    
DOI: 10.1002/term.1839     Document Type: Article

References (46)

1. Beavo JA, Brunton LL. 2002; Cyclic nucleotide research – still expanding after half a century. Nat Rev Mol Cell Biol 3: 710–718.
2. Bessa PC, Casal M, Reis RL. 2008; Bone morphogenetic proteins in tissue engineering: the road from laboratory to clinic, part II (BMP delivery). J Tissue Eng Regen Med 2: 81–96.
3. Brouwers L, Iskar M, Zeller G, et al. 2011; Network neighbors of drug targets contribute to drug side-effect similarity. PLoS One 6: e22187; doi: 10.1371/journal.pone.0022187.
4. Chen J, Wang X, Zhu J, et al. 2004; Effects of Ginkgo biloba extract on number and activity of endothelial progenitor cells from peripheral blood. J Cardiovasc Pharmacol 43: 347–352.
5. Chiu LL, Weisel RD, Li RK, et al. 2011; Defining conditions for covalent immobilization of angiogenic growth factors onto scaffolds for tissue engineering. J Tissue Eng Regen Med 5: 69–84.
6. Christensen AE, Selheim F, de Rooij J, et al. 2003; cAMP analog mapping of Epac1 and cAMP kinase. Discriminating analogs demonstrate that Epac and cAMP kinase act synergistically to promote PC-12 cell neurite extension. J Biol Chem 278: 35394–35402.
7. Cui Q, Dighe AS, Irvine JN. 2013; Combined angiogenic and osteogenic factor delivery for bone regenerative engineering. Curr Pharm Des 19: 3374–3383.
8. Doorn J, Fernandes HA, Le BQ, et al. 2013; A small molecule approach to engineering vascularized tissue. Biomaterials 34: 3053–3063.
9. Doorn J, Leusink M, Groen N, et al. 2012a; Diverse effects of cyclic AMP variants on osteogenic and adipogenic differentiation of human mesenchymal stromal cells. Tissue Eng A 18: 1431–1442.
10. Doorn J, Siddappa R, van Blitterswijk CA, et al. 2012b; Forskolin enhances in vivo bone formation by human mesenchymal stromal cells. Tissue Eng A 18: 558–567.
11. Egusa H, Saeki M, Doi M, et al. 2010; A small-molecule approach to bone regenerative medicine in dentistry. J Oral Biosci 52: 107–118.
12. Ennett AB, Kaigler D, Mooney DJ. 2006; Temporally regulated delivery of VEGF in vitro and in vivo. J Biomed Mater Res A 79: 176–184.
13. Folkman J, Haudenschild C. 1980; Angiogenesis by capillary endothelial cells in culture. Trans Ophthalmol Soc UK 100: 346–353.
14. Giancotti FG, Ruoslahti E. 1999; Integrin signaling. Science 285: 1028–1032.
15. He J, Qian X, Carpenter R, et al. 2013; Repression of miR-143 mediates Cr(VI)-induced tumor angiogenesis via IGF-IR/IRS1/ERK/IL-8 pathway. Toxicol Sci 134: 26–38.
16. Ho WC, Greene RM, Shanfeld J, et al. 1982; Cyclic nucleotides during chondrogenesis: concentration and distribution in vivo and in vitro. J Exp Zool 224: 321–330.
17. Katagiri T, Yamaguchi A, Komaki M, et al. 1994; Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J Cell Biol 127: 1755–1766.
18. Kim J, Sharma A, Runge B, et al. 2012; Osteoblast growth and bone-healing response to three-dimensional poly(ε-caprolactone fumarate) scaffolds. J Tissue Eng Regen Med 6: 404–413.
19. Kosher RA, Savage MP. 1980; Studies on the possible role of cyclic AMP in limb morphogenesis and differentiation. J Embryol Exp Morphol 56: 91–105.
20. Lamalice L, Le Boeuf F, Huot J. 2007; Endothelial cell migration during angiogenesis. Circ Res 100: 782–794.
21. Lamb D, Steinberg RA. 2002; Anti-proliferative effects of 8-chloro-cAMP and other cAMP analogs are unrelated to their effects on protein kinase A regulatory subunit expression. J Cell Physiol 192: 216–224.
22. Laurencin CT, Khan Y. 2012; Regenerative engineering. Sci Transl Med 4: 160ed9.
23. Lee K, Silva EA, Mooney DJ. 2010; Growth factor delivery-based tissue engineering: general approaches and a review of recent developments. J R Soc Interface 8: 153–170.
24. Lo KWH, Kan HM, Laurencin CT. 2013; Short term treatment of small molecule phenamil induced a protracted osteogenic effect on osteoblast-like MC3T3-E1 cells. J Tissue Eng Regen Med 19: 3374–3383.
25. Lo KWH, Ashe KM, Kan HM, et al. 2012a; The role of small molecules in the musculoskeletal regeneration. Regen Med 7: 535–549.
26. Lo KWH, Kan HM, Ashe KM, et al. 2012b; The small molecule PKA-selective cyclic AMP analogue as an inducer of osteoblast-like cells differentiation and mineralization. J Tissue Eng Regen Med 6: 40–48.
27. Lo KWH, Ulery BD, Ashe KM, et al. 2012c; Evaluating the feasibility of utilizing small molecule phenamil as a novel biofactor factor for bone regenerative engineering. J Tissue Eng Regen Med doi: 10.1002/term.1573.
28. Lo KWH, Ulery BD, Ashe KM, et al. 2012d; Studies of bone morphogenetic protein based surgical repair. Adv Drug Deliv Rev 64: 1277–1291.
29. Lo KWH, Ulery BD, Deng M, et al. 2011a; Current patents on osteoinductive molecules for bone tissue engineering. Recent Patents Biomed Eng 4: 153–167.
30. Lo KWH, Ashe KM, Kan HM, et al. 2011b; Activation of cyclic AMP/protein kinase A signaling pathway enhances osteoblast cell adhesion on biomaterials for regenerative engineering. J Orthop Res 29: 602–608.
31. Malich G, Markovic B, Winder C. 1997; The sensitivity and specificity of the MTS tetrazolium assay for detecting the in vitro cytotoxicity of 20 chemicals using human cell lines. Toxicology 124: 179–192.
32. Masuya K, Teno N. 2010; Small molecules for bone diseases. Expert Opin Ther Pat 20: 563–582.
33. Namkoong S, Kim CK, Cho YL, et al. 2009; Forskolin increases angiogenesis through the coordinated cross-talk of PKA-dependent VEGF expression and Epac-mediated PI3K/Akt/eNOS signaling. Cell Signal 21: 906–915.
34. Osusky KL, Hallahan DE, Fu A, et al. 2004; The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 7: 225–233.
35. Ozdemir T, Higgins AM, Brown JL. 2013; Osteoinductive biomaterial geometries for bone regenerative engineering. Curr Pharm Des 19: 3446–3455.
36. Rangarajan S, Enserink JM, Kuiperij HB, et al. 2003; Cyclic AMP induces integrin-mediated cell adhesion through Epac and Rap1 upon stimulation of the β2-adrenergic receptor. J Cell Biol 160: 487–493.
37. Schwede F, Maronde E, Genieser H, et al. 2000; Cyclic nucleotide analogs as biochemical tools and prospective drugs. Pharmacol Ther 87: 199–226.
38. Sefcik LS, Petrie Aronin CE, Botchwey EA. 2008; Engineering vascularized tissues using natural and synthetic small molecules. Organogenesis 4: 215–227.
39. Segar CE, Ogle ME, Botchwey EA. 2013; Regulation of angiogenesis and bone regeneration with natural and synthetic small molecules. Curr Pharm Des 19: 3403–3419.
40. Siddappa R, Martens A, Doorn J, et al. 2008; cAMP/PKA pathway activation in human mesenchymal stem cells in vitro results in robust bone formation in vivo. Proc Natl Acad Sci U S A 105: 7281–7286.
41. Solursh M, Reiter R, Ahrens PB, et al. 1979; Increase in levels of cyclic AMP during avian limb chondrogenesis in vitro. Differentiation 15: 183–186.
42. Southgate K, Newby AC. 1990; Serum-induced proliferation of rabbit aortic smooth muscle cells from the contractile state is inhibited by 8-Br-cAMP but not 8-Br-cGMP. Atherosclerosis 82: 113–123.
43. Starzec AB, Spanakis E, Nehme A, et al. 1994; Proliferative responses of epithelial cells to 8-bromo-cyclic AMP and to a phorbol ester change during breast pathogenesis. J Cell Physiol 161: 31–38.
44. Sun J, Blaskovich MA, Jain RK, et al. 2004; Blocking angiogenesis and tumorigenesis with GFA-116 a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor. Cancer Res 64: 3586–3592.
45. Tischer T, Aryee S, Wexel G, et al. 2010; Tissue engineering of the anterior cruciate ligament–sodium dodecyl sulfate-acellularized and revitalized tendons are inferior to native tendons. Tissue Eng A 16: 1031–1040.
46. Wieghaus KA, Capitosti SM, Anderson CR, et al. 2006; Small molecule inducers of angiogenesis for tissue engineering. Tissue Eng 12: 1903–1913.